On the difficulty of validating molecular generative models realistically: a case study on public and proprietary data.

J Cheminform

Centre for Molecular Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.

Published: November 2023

AI Article Synopsis

  • The study discusses the challenges in validating deep generative models for drug discovery, pointing out that retrospective validation is biased since it can't assess newly generated molecules accurately; meanwhile, prospective validation is costly and influenced by human choices.
  • Researchers aimed to see if a model (REINVENT) trained on early-stage drug compounds could effectively generate middle or late-stage compounds, using data from both public and in-house projects.
  • Results showed that rediscovery rates of middle/late-stage compounds were significantly higher in public projects compared to in-house projects, revealing the limitations of using generative models in real-world drug discovery compared to traditional human-driven methods.

Article Abstract

While a multitude of deep generative models have recently emerged there exists no best practice for their practically relevant validation. On the one hand, novel de novo-generated molecules cannot be refuted by retrospective validation (so that this type of validation is biased); but on the other hand prospective validation is expensive and then often biased by the human selection process. In this case study, we frame retrospective validation as the ability to mimic human drug design, by answering the following question: Can a generative model trained on early-stage project compounds generate middle/late-stage compounds de novo? To this end, we used experimental data that contains the elapsed time of a synthetic expansion following hit identification from five public (where the time series was pre-processed to better reflect realistic synthetic expansions) and six in-house project datasets, and used REINVENT as a widely adopted RNN-based generative model. After splitting the dataset and training REINVENT on early-stage compounds, we found that rediscovery of middle/late-stage compounds was much higher in public projects (at 1.60%, 0.64%, and 0.21% of the top 100, 500, and 5000 scored generated compounds) than in in-house projects (where the values were 0.00%, 0.03%, and 0.04%, respectively). Similarly, average single nearest neighbour similarity between early- and middle/late-stage compounds in public projects was higher between active compounds than inactive compounds; however, for in-house projects the converse was true, which makes rediscovery (if so desired) more difficult. We hence show that the generative model recovers very few middle/late-stage compounds from real-world drug discovery projects, highlighting the fundamental difference between purely algorithmic design and drug discovery as a real-world process. Evaluating de novo compound design approaches appears, based on the current study, difficult or even impossible to do retrospectively.Scientific Contribution This contribution hence illustrates aspects of evaluating the performance of generative models in a real-world setting which have not been extensively described previously and which hopefully contribute to their further future development.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664602PMC
http://dx.doi.org/10.1186/s13321-023-00781-1DOI Listing

Publication Analysis

Top Keywords

middle/late-stage compounds
16
generative models
12
generative model
12
compounds
9
case study
8
retrospective validation
8
public projects
8
compounds in-house
8
in-house projects
8
drug discovery
8

Similar Publications

Article Synopsis
  • The study discusses the challenges in validating deep generative models for drug discovery, pointing out that retrospective validation is biased since it can't assess newly generated molecules accurately; meanwhile, prospective validation is costly and influenced by human choices.
  • Researchers aimed to see if a model (REINVENT) trained on early-stage drug compounds could effectively generate middle or late-stage compounds, using data from both public and in-house projects.
  • Results showed that rediscovery rates of middle/late-stage compounds were significantly higher in public projects compared to in-house projects, revealing the limitations of using generative models in real-world drug discovery compared to traditional human-driven methods.
View Article and Find Full Text PDF

Sec-O-glucosylhamaudol (SOG), an active flavonoid compound derived from the root of (Turcz. ex Ledeb.) Schischk.

View Article and Find Full Text PDF

[Effect of lead exposure on gene expression of Fgf3 in zebrafish embryonic development].

Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi

October 2012

School of Environmental Science and Public Health, Wenzhou Medical College, Wenzhou 325035, China.

Objective: To investigate the effect of lead exposure on the gene expression of fibroblast growth factor 3 (Fgf3) in zebrafish embryonic development and the mechanism of lead-induced embryonic developmental toxicity.

Methods: The embryos of zebrafish (wild types A and B) were exposed to lead acetate (PbAc) at the doses of 0, 0.1, 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!